- Niraparib Plus Abiraterone/Prednisone Maintains rPFS Benefit in HRR Gene–Altered mCRPC.
- Wrigley N.
- OncLive. 2023 Feb 17.
- Conference report
- Free Full Text
•• Identifier: NCT03748641: A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (MAGNITUDE). (ClinicalTrials.gov . Accessed 2023 Feb 18.)
- Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
- Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U, Lindberg H, Morris D, Nolè F, Staffurth J, Redfern C, Sáez MI, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes CA, Watkins SP, Chowdhury S, Ryan CJ, Bryce AH; TRITON3 Investigators.
- N Engl J Med. 2023 Feb 16. doi: 10.1056/NEJMoa2214676. Epub ahead of print.
- PMID: 36795891
- PubMed abstract
- Source abstract
•• Identifier: NCT02975934: A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3). (ClinicalTrials.gov . Accessed 2023 Feb 16.)
•• Research news: Rucaparib Bests Physician's Choice for BRCA+ mCRPC. (OncLive)